Anzeige
Mehr »
Samstag, 18.10.2025 - Börsentäglich über 12.000 News
Europa rüstet Drohnenabwehr auf - und diese Aktie könnte die Technologie dazu liefern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
03.09.Treeline reaps $200M series A extension, plucks first 3 clinical candidates
03.09.Pfizer, Valneva boosted by updated vaccine data ahead of moment in the Lyme-light
03.09.Novartis returns to Argo for multifaceted $5B cardiovascular collab
02.09.Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US
02.09.Boston biotech Radiance offers China firm $1B-plus for rights to next-gen ADC
02.09.As Cytokinetics awaits FDA approval decision, phase 3 cardio win sends stock soaring
02.09.After strategic pivot, Editas lays out plan to target high cholesterol with gene editing
02.09.Amgen to build $600M R&D site, hire hundreds in California
02.09.Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line
02.09.Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods
02.09.Novartis takes another shot at alpha-synuclein with $2.2B Arrowhead CNS deal
02.09.Merck dives into regulatory talks after oral PCSK9 delivers 3rd phase 3 win
02.09.Zymeworks drops clinical-stage T-cell engager after assessing benefit-risk profile
02.09.Chasing pharma heavyweights, Upstream posts phase 2 sinusitis win but stock flows downhill
02.09.Lilly ends 2 of 3 midstage trials for oral GLP-1 contender naperiglipron
01.09.AstraZeneca gears up for FDA filing after sharing details of baxdrostat's hypertension success
01.09.Roche sees Alnylam hypertension RNAi drug flunk trial but still plans phase 3 push
29.08.Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen
29.08.Fosun rises again, inking 3rd inflammatory disease deal in 3 weeks
29.08.BeOne's BCL2 drug hits primary endpoint, setting stage for filings to take up blood cancer mantle
28.08.Months after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60M
28.08.FDA considers noninvasive liver endpoint for clinical trials, sending MASH biotechs' shares up
28.08.Flagship taps IQVIA as biotech support for company fleet
28.08.Prothena's Alzheimer's trial hit by ARIA showstopper, resulting in 'non-competitive' profile
27.08.Exelixis to lay off 130 employees, shut down Pennsylvania site in post-pandemic downsizing